MDT-AP-0759
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 9.36
- os_event
- true
- age_years
- 4
- sex
- M
- new_clusters
- C5
- umap1_2d
- 2.415796914
- umap2_2d
- 2.231250821
- umap1_3d
- -0.057043398
- umap2_3d
- -2.712022194
- umap3_3d
- -2.016836414
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.390
- MYOGENESIS+0.350
- KRAS_SIGNALING_DN+0.310
- APICAL_SURFACE+0.300
- INTERFERON_GAMMA_RESPONSE+0.250
- APICAL_JUNCTION+0.210
- HEDGEHOG_SIGNALING+0.190
- WNT_BETA_CATENIN_SIGNALING+0.150
- NOTCH_SIGNALING+0.140
- IL6_JAK_STAT3_SIGNALING+0.130
Top 10 suppressed
- E2F_TARGETS-0.680
- G2M_CHECKPOINT-0.610
- MYC_TARGETS_V1-0.550
- MYC_TARGETS_V2-0.450
- DNA_REPAIR-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.370
- PROTEIN_SECRETION-0.360
- MITOTIC_SPINDLE-0.320
- ANGIOGENESIS-0.260
- MTORC1_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1273 | Med | Medulloblastoma | 0.904 |
| 2 | s0112320 | — | — | 0.863 |
| 3 | MDT-AP-0820 | Med | Medulloblastoma | 0.857 |
| 4 | SRR12202413 | — | — | 0.854 |
| 5 | SAMN03290904 | — | — | 0.851 |
| 6 | MDT-AP-1132 | Med | Medulloblastoma | 0.844 |
| 7 | TCGA-55-8513-01A-11R-2403-07 | — | cohortA1 | 0.837 |
| 8 | TCGA-CF-A47V-01A-11R-A23W-07 | — | — | 0.819 |
| 9 | TCGA-QK-A652-01A-11R-A30B-07 | — | — | 0.811 |
| 10 | TCGA-CV-A45R-01A-11R-A24H-07 | — | — | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.250 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.060 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.060 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |